ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2012
Expression and association of HER2 with prognosis in early-stage (T1-T2N0M0) non-small cell lung cancer.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 9 citations in OpenAlex.
- Precise diagnosis and prognosis assessment of malignant lung nodules: a narrative review.Journal of thoracic disease · 2024Review
- Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients.Journal of Cancer · 2017Article
- Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2014Review
- CARMA3 overexpression accelerates cell proliferation and inhibits paclitaxel-induced apoptosis through NF-κB regulation in breast cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures.Translational lung cancer research · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expression of human epidermal growth factor receptor 2 (HER2) is related to tumor progression in many human malignancies. This study evaluated the significance of HER2 in early-stage non-small cell lung cancer (NSCLC). Specimens were obtained from 172 patients with early-stage (T1-T2N0M0) NSCLC, which included T1N0M0 (n = 52) and T2N0M0 (n = 120). The expression of HER2 was determined by immunohistochemistry (IHC). HER2 expression and its relationship with clinicopathological parameters and survival were analyzed. The expression of HER2 was significantly higher in the non-squamous cell carcinoma than in the squamous cell carcinoma (74.3 % vs. 53.7 %, p = 0.008). HER2 expression and tumor size were independent prognostic indicators in the multivariate analysis (p = 0.007 and p = 0.015, respectively). Expression of HER2 indicated a worse 5-year overall survival (65 % vs. 86 %, p = 0.014), especially for stages IB and IIA diseases (p = 0.035 and p = 0.043, respectively) and adenocarcinoma (p = 0.047). Therefore, HER2 may be related with the pathogenesis of NSCLC and act as an unfavorable prognostic factor in T1N0M0 and T2N0M0 NSCLC, especially in stages IB and IIA diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.